Home / Products / Cancer / Blood Cancer - Haematological Cancer

Blood Cancer - Haematological Cancer


Available treatments for Blood Cancer - Haematological Cancer
You can order a treatment for Blood Cancer - Haematological Cancer via TheSocialMedwork if it has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Read more about Blood Cancer - Haematological Cancer below.
drip
View Product

Beleodaq

(belinostat)

by: Spectrum Pharmaceuticals
for: Blood Cancer
from: 3105.00
• FDA approved (USA)
drip
View Product

Besponsa

(inotuzumab ozogamicin)

by: Pfizer
for: Acute Lymphoblastic Leukemia
from: 14720.00
• EMA approved (EU)
• FDA approved (USA)

drip
View Product

Blincyto

(blinatumomab)

by: Amgen
for: Blood Cancer
from: 3105.00
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

drip
View Product

Darzalex

(daratumumab)

by: Janssen Biotech
for: Blood Cancer
from: 690.00
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

drip
View Product

Empliciti

(elotuzumab)

by: Bristol-Myers Squibb
for: Blood Cancer
from: 1684.75
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

drip
View Product

Keytruda

(pembrolizumab)

by: Merck & co
for: Head and Neck Cancer / Lung Cancer / Urothelial Carcinoma / Skin Cancer / Lymphoma / MSI-H or dMMR solid tumours / Gastric Cancer
from: 1626.51
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

pill
View Product

Ninlaro

(ixazomib)

by: Takeda Pharmaceuticals
for: Blood Cancer
from: 9861.25
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

drip
View Product

Opdivo

(nivolumab)

by: Bristol-Myers Squibb
for: Colorectal Cancer / Head and Neck Cancer / Hodgkin Lymphoma / Kidney Cancer / Lung Cancer / Skin Cancer / Bladder Cancer / Liver Cancer
from: 585.38
• EMA approved (EU)
• FDA approved (USA)
• PMDA approved (JAP)
• TGA approved (AUS)

pill
View Product

Rydapt

(midostaurin)

by: Novartis
for: Blood Cancer
from: 8774.50
• EMA approved (EU)
• FDA approved (USA)

pill
View Product

Venclexta / Venclyxto

(venetoclax)

by: AbbVie
for: Blood Cancer
from: 1063.75
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

pill
View Product

Venclexta / Venclyxto

(venetoclax)

by: AbbVie
for: Blood Cancer
from: 4082.50
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

unknown
Enquire now

We may still be able to get it for you, provided that:

• it hasn't been approved and/or isn't available in your country
• you and your treating doctor have evaluated that the medicine is suitable for you, and your doctor writes a prescription for it.


About blood cancer - haematological cancer

Blood cancer is a type of cancer that affects the production and function of blood cells. There are several different types of blood cancer depending the type of blood cell and how it is affected. Often the cancer starts in the bone marrow where blood is produced from stem cells. Stem cells in the bone marrow mature and develop into three types of blood cells: red blood cells, white blood cells, or platelets. In most blood cancers, the normal blood cell development process is interrupted by the uncontrolled growth of an abnormal type of blood cell. These abnormal blood cells, or cancerous cells, prevent the blood from performing many of its usual functions, like fighting off infections or preventing serious bleeding [1].

The 3 main types of blood cancer are leukemia, lymphoma and myeloma [1]:

- Leukemia is caused by the rapid production of abnormal white blood cells. These abnormal white blood cells are not able to fight infection and impair the ability of the bone marrow to produce red blood cells and platelets. Leukemia can be either acute or chronic and is classified as either lymphocytic or myelogenous, depending on whether it affects premature lymphocytes or premature red blood cells, white blood cells, and platelets. There are four broad classifications of leukemia: acute lymphocytic leukemia (ALL) – the most common form of childhood leukemia; acute myelogenous leukemia (AML); chronic lymphocytic leukemia (CLL); and chronic myelogenous leukemia (CML). Leukemia occurs in both adults and children [2].

- Lymphoma is the most common type of blood cancer and occurs when cells of the immune system called lymphocytes – a type of white blood cell – grow and multiply uncontrollably. It’s two main forms are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with the latter being more common than the former [3]. Depending on which mechanism of the white blood cells is affected, cancer can develop in several different ways, and within HL and NHL several subclasses can be differentiated. Lymphoma may develop in many parts of the body, including the lymph nodes, spleen, bone marrow, blood or other organs [4].

- Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. They mature from a type of cells of the immune system (B-cells) and make the antibodies that help the body attack and kill germs. When plasma cells become cancerous and grow out of control, they can produce a tumour called a plasmacytoma. These tumours generally develop in a bone, but they are also rarely found in other tissues. One single cancerous plasma cell is called an isolated (or solitary) plasmacytoma. More plasmacytomas constitute a multiple myeloma [5].

The incidence varies per type of blood cancer, with some being very common and others being rather rare. With 386,000 new cases worldwide, NHL was the 10th most common type among all cancers in 2012, followed by leukemia with 352,000 new cases. In 2012, multiple myeloma and HL were the 23rd and 25th most common cancers worldwide, with 114,000 and 66,000 new cases respectively [6].


Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.